Warhound Raises $200 Million to Engineer Military Working Dogs

Warhound, a company that intends to genetically engineer dogs for the U.S. military, law enforcement and emergency response teams, emerged from stealth on October 22, 2026, with $200 million in funding. The round valued the company at $1.2 billion, according to TechCrunch. Investors include In-Q-Tel, Sequoia and 8VC.

The company was conceived by Colossal Biosciences' Ben Lamm and Anduril's Palmer Luckey. Colossal owns equity in Warhound and supports it by licensing its technology. Luckey does not own equity and is a partner only. Lamm said he met Luckey about a year ago at a conference, where Luckey raised the need to do more for working dogs in the U.S. military.

According to Warhound, more than 80% of working dogs used by the U.S. military come from Europe, and less than half of them are fit for service. Those two figures are the company's stated reason for existing.

The technical approach rests on biobanked cell lines, meaning frozen, stored cell cultures that can be drawn on later. Warhound has banked cells from Belgian Malinois and German Shepherds, which it identifies as the top-performing working breeds. The company plans to edit dog genes, which means making targeted changes to the DNA itself, to add performance-enhancing genes and remove detrimental ones. The goal is a new type of dog suited to demanding missions. Colossal's technology is the foundation for that work. Viagen, a Colossal-owned company, is partnering with Warhound to clone the animals, producing genetically identical copies from a donor cell.

The timeline is an expectation rather than a completed milestone. Warhound's first batch of dogs was about to be cloned and incubated. The company expects the dogs to be born early next year and to enter service within the following two years.

Anduril's role is on the equipment side. The company will provide software and hardware enhancements for Warhound dogs, including protection vests and eye goggles intended for situational awareness and coordination.

The broader context here is that the program sits where three fields rarely share a roadmap: animal biotechnology that touches heritable genetics, defense procurement, and sensor-equipped field hardware. Cloning and gene editing in a working breed are established research tools. Turning them into a repeatable pipeline of service animals is a different engineering and governance problem. The performance claims, the choice of Belgian Malinois and German Shepherd lines, and the eventual edits will all have to show up in animals working in the field before the thesis can be judged.

In my view, the most useful question is not whether the technology works in principle but how the company will measure success. A dog that performs better on paper must still pass the same handler, environment and reliability tests that current working dogs face. Warhound's own figures on European sourcing and fitness for service give it a clear benchmark, and the first cohort will be judged against those numbers.

There is also a welfare and oversight dimension that the announcement leaves open. Editing animals for specific traits and then cloning them raises questions about health outcomes, lifetime care and who is accountable for the animals once they enter service. Those questions will matter as much as the performance numbers.

If the program delivers, the upside is practical. A domestic pipeline could reduce dependence on imported animals, and selecting trait profiles from a biobank could give handlers dogs that match specific missions more closely. Warhound's timeline is short by the standards of animal breeding, which is why the coming year, when the first cloned dogs are expected to be born, is the first point at which the company's claims can be tested against observable results.